• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon

    12/16/25 7:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email

    ISS Says It Would Not Be "Unreasonable for a Shareholder to Remain Opposed" to the Deal

    Broadwood Encourages Shareholders to Follow the Recommendations of Proxy Advisory Firms Glass Lewis and Egan-Jones, Both of Whom Recommend Shareholders Vote "AGAINST" the Proposed Transaction

    Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today commented on a report published by Institutional Shareholder Services Inc. ("ISS"), an independent proxy advisory firm, which reiterates that firm's significant concerns regarding the proposed acquisition of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) by Alcon Inc. ("Alcon") (NYSE:ALC).

    ISS stated in its latest report on the proposed sale of STAAR to Alcon:

    "The initial sale process was deeply flawed, the circumstances create uncertainty about whether the go-shop could have cured concerns, and STAA has provided shareholders with no reason to rely on its efforts. … [In addition,] it is still difficult to fully assess the adequacy of the offer." 1

    ISS made the following additional observations:

    • "STAA has made it difficult for shareholders to trust the statements and actions of the board and management team."
    • "STAA did not clearly disclose in initial filings that approval of the amended merger agreements was not unanimous. This critical information was instead disclosed in supplemental filings."
    • "[T]here are significant concerns with the sale process, and these were not fully cured by the 30-day go-shop."
    • "[S]hareholders continue to have a reason to question whether the board's messaging about downside risk from an operational perspective is completely credible."
    • "[I]t is now evident that shareholders cannot rely on the incumbent leadership team."

    ISS concluded: "[I]t would not necessarily be unreasonable for a shareholder to remain opposed to this transaction…."

    ISS's skepticism about the transaction is consistent with the views of the two other prominent shareholder advisory firms, Glass, Lewis & Co., LLC ("Glass Lewis") and Egan-Jones Ratings Company ("Egan-Jones"), both of whom are recommending that shareholders vote "AGAINST" the proposed transaction.

    In its updated report on December 5, 2025, Egan Jones said: "[W]e believe the credibility and integrity of the transaction have been compromised by the previously non-competitive process. Furthermore, because the same board and executive management team oversaw both the original merger and the subsequent amendment and go-shop process, our concerns regarding objectivity and fairness remain the same."

    Glass Lewis concluded in its December 11, 2025, report that "we do not believe there exists persuasive cause for investors to endorse the revised Alcon arrangement."

    Neal C. Bradsher, Founder and President of Broadwood, reacted to the recent proxy advisor reports:

    "The proposed sale to Alcon has been met with overwhelming opposition from STAAR shareholders, proxy advisory firms, and even from within STAAR's own boardroom. We reject ISS's inexplicable decision to offer ‘cautionary support' for the proposed transaction in the face of what ISS itself described as uncured process concerns, skepticism that Alcon's revised offer represents full value for STAAR, and an inability of shareholders to rely on STAAR's Board and management team. ISS's condemnation of the integrity of the Board and management team reinforces our strong belief that this transaction should be voted down and followed by significant changes to STAAR's leadership group.

    It is a sad day when the best argument for agreeing to the sale of a company is that the leadership team and board are so unreliable and lacking in credibility that shareholders cannot count on strong execution or proper stewardship in the future. Notwithstanding the Board and leadership team's failures of oversight and execution, we remain confident in STAAR's product and market opportunity and believe STAAR is worth substantially more than Alcon is offering today.

    Notably, just last year, Alcon offered twice as much for the Company, and STAAR's long-term prospects have not changed meaningfully. Since this misbegotten transaction was proposed, STAAR has downplayed its own performance and future opportunity – at every turn – to justify the deal. However, as ISS noted, shareholders have no reason to trust the judgment or integrity of STAAR's Board in making a determination about the deal consideration, and the Board chose not to seek advice from its financial advisor regarding the fairness of Alcon's revised proposal.

    Shareholders should not throw in the towel at a discounted price just because they cannot trust the current Board and management team to properly run the Company or a sale process. Nor should shareholders reward a misaligned and poorly performing management team and conflicted Board with a lucrative exit. What message would that send to all other boards?

    We are taking the necessary steps to call a special meeting of shareholders to remove the three directors we feel are most responsible for this deeply flawed and conflicted transaction. We also remain prepared to work with our fellow shareholders to identify qualified independent and experienced director candidates to ensure that STAAR is positioned to succeed and maximize value for all shareholders."

    Broadwood encourages its fellow shareholders to review its presentations, proxy materials, and press releases, all of which are available at www.LetSTAARShine.com, and to vote "AGAINST" the proposed transaction with Alcon.

    If you have any questions or require any assistance with voting your shares, please contact our proxy solicitor, Saratoga Proxy Consulting LLC, by calling (212) 257-1311 or toll free at (888) 368-0379, or by email at [email protected]. If you have already voted for the merger, you may change your vote by voting a later-dated proxy "AGAINST" the deal. Only your latest dated vote counts.

    About Broadwood

    Broadwood Partners, L.P. is managed by Broadwood Capital, Inc. Broadwood Capital is a private investment firm based in New York City. Neal Bradsher is the President of Broadwood Capital.

    Certain Information Concerning the Participants

    Special Meeting of Shareholders Originally Scheduled for October 23, 2025

    Broadwood Partners, L.P., Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn, Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the "Participants") are participants in the solicitation of proxies from the shareholders of the Company in connection with the special meeting of shareholders originally scheduled for October 23, 2025 and most recently postponed to be held on December 19, 2025 (including any further adjournments, postponements, reschedulings or continuations thereof, the "Proposed Merger Special Meeting"). The Participants have filed a definitive proxy statement on Schedule 14A (the "Definitive Proxy Statement") and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies from the Company's shareholders for the Proposed Merger Special Meeting. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE "SEC") BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE PROPOSED MERGER SPECIAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The Definitive Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of the Company's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

    Special Meeting of Shareholders to Remove Members of the Board

    The Participants also intend to file a definitive proxy statement and an accompanying GREEN Proxy Card with the SEC to be used to solicit proxies with respect to removing members of the Board and any other proposals that may come before a future and yet to be called or otherwise scheduled special meeting of shareholders (including any adjournments, postponements, reschedulings or continuations thereof, the "Shareholder Meeting"). The Shareholder Meeting will be separate, distinct and unrelated to the Proposed Merger Special Meeting, and the Participants believe that the Shareholder Meeting will have no effect on the outcome of the Proposed Merger Special Meeting. The Participants do not believe that there is any lawful reason that would prevent or prohibit the Participants from calling the Shareholder Meeting, regardless of the outcome of the shareholder vote at the Proposed Merger Special Meeting, and do not make any representation related to whether the Company may contest, or otherwise challenge, the Participants' ability to call the Shareholder Meeting. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SHAREHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some or all of the Company's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

    Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on November 21, 2025 and is available here.

    ____________________

    1

    Permission to use quotes was neither sought nor obtained.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251216554418/en/

    Investor Contacts

    John Ferguson / Joseph Mills

    Saratoga Proxy Consulting LLC

    [email protected]

    [email protected]

    (212) 257-1311

    (888) 368-0379



    Media Contacts

    Scott Deveau / Jeremy Jacobs

    August Strategic Communications

    [email protected]

    (323) 892-5562

    Get the next $ALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC
    $STAA

    CompanyDatePrice TargetRatingAnalyst
    Alcon Inc.
    $ALC
    2/26/2026$97.00Equal Weight → Overweight
    Wells Fargo
    STAAR Surgical Company
    $STAA
    2/3/2026$26.00Neutral
    Wedbush
    Alcon Inc.
    $ALC
    1/30/2026Mkt Perform
    William Blair
    Alcon Inc.
    $ALC
    1/20/2026Hold → Buy
    Deutsche Bank
    STAAR Surgical Company
    $STAA
    1/16/2026$13.00Underweight
    Morgan Stanley
    Alcon Inc.
    $ALC
    1/9/2026Buy → Hold
    Stifel
    Alcon Inc.
    $ALC
    12/11/2025$75.00Buy → Underperform
    BofA Securities
    Alcon Inc.
    $ALC
    8/21/2025Overweight → Neutral
    Analyst
    More analyst ratings

    $ALC
    $STAA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Broadwood Partners, L.P. bought $12,266,545 worth of shares (670,213 units at $18.30) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/13/26 7:59:59 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $606,138 worth of shares (27,485 units at $22.05) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    1/13/26 9:30:12 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $8,817,664 worth of shares (406,653 units at $21.68) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    1/8/26 7:31:31 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alcon Publishes Agenda for 2026 Annual General Meeting

    Alcon welcomes its shareholders to its fourth in-person AGM Alcon Board of Directors proposes to elect R. Scott Herren as a new independent Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 30, 2026. Alcon is pleased to welcome shareholders to its fourth in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect R. Scott Herren as a new independent Board member. An accomplished financial executive with thirty-

    4/2/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

    Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ:LNSR) to terminate the companies' previously announced merger agreement. "Alcon continues to believe that the acquisition of LENSAR would have significantly enhanced FLACS innovation and competition to the benefit of surgeons and patients. However, the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission's opposition. Alcon remains committed to advancing cataract surgery by d

    3/16/26 4:57:00 PM ET
    $ALC
    $LNSR
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments

    STAAR Surgical Issues Shareholder Letter

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday, March 3 after the market close. STAAR's results release can be found here: https://investors.staar.com/news-and-events/press-releases. Fellow Shareholders, This past month marked an important transition for our company as we stepped into the roles of Interim co-Chief Executive Officers. We are honored by the Board's confidence and deeply grateful for the dedication of our employees, the loyalty of our customers, and the opportunity to serve you—our shareholders. It is with great pleasure

    3/3/26 4:02:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alcon upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Alcon from Equal Weight to Overweight and set a new price target of $97.00

    2/26/26 7:10:22 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Wedbush initiated coverage on STAAR Surgical with a new price target

    Wedbush initiated coverage of STAAR Surgical with a rating of Neutral and set a new price target of $26.00

    2/3/26 8:08:13 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    William Blair initiated coverage on Alcon

    William Blair initiated coverage of Alcon with a rating of Mkt Perform

    1/30/26 6:43:20 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ALC
    $STAA
    SEC Filings

    View All

    Interim Co-CEO and Pres. & COO Foust Warren converted options into 37,500 shares, increasing direct ownership by 144% to 63,588 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/16/26 5:00:16 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Interim Co-CEO and CFO Andrews Deborah J

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/16/26 5:00:17 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Chief Development Officer Michna Magda converted options into 23,773 shares and covered exercise/tax liability with 8,529 shares, increasing direct ownership by 105% to 29,668 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/16/26 5:00:14 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    4/2/26 4:34:32 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by STAAR Surgical Company

    SCHEDULE 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    3/27/26 1:17:37 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - STAAR SURGICAL CO (0000718937) (Filer)

    3/3/26 4:05:29 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Financials

    Live finance-specific insights

    View All

    Alcon Publishes Agenda for 2026 Annual General Meeting

    Alcon welcomes its shareholders to its fourth in-person AGM Alcon Board of Directors proposes to elect R. Scott Herren as a new independent Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 30, 2026. Alcon is pleased to welcome shareholders to its fourth in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect R. Scott Herren as a new independent Board member. An accomplished financial executive with thirty-

    4/2/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

    Confident in China Progress and Future Roadmap A Clear Path Toward Sustainable Profitability and Growth Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation STAAR Interim co-CEOs Issue Letter to Shareholders Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/new

    3/3/26 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales

    Fourth-quarter 2025 sales of $2.7 billion, up 9% on a reported basis, or up 7% constant currency1 (cc), versus fourth-quarter 2024 Fourth-quarter 2025 diluted EPS of $0.44; core diluted EPS2 of $0.78 Generated $2.3 billion of cash from operations and $1.7 billion of free cash flow3 in full-year 2025 Returned $848 million to shareholders through share repurchases and dividends Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2025. For the fourth quarter of 2025, sales were $2.7 billion, up 9% on a reported basis and up 7% on a constant curren

    2/24/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Leadership Updates

    Live Leadership Updates

    View All

    STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

    Search Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the "Board") has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work together with the other members of the executive leadership team, with support and guidance from the Board, as they lead the Company and manage its day-to-day operations.

    2/2/26 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

    Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital have Joined STAAR Board STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have Stepped Down from the Board Farrell will Remain CEO until January 31, 2026 STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates ("Broadwood"), which together own 31% of STAAR's outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5%

    1/15/26 8:30:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    9/6/24 9:51:09 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/13/24 5:14:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by Alcon Inc.

    SC 13G - ALCON INC (0001167379) (Subject)

    2/13/24 3:47:46 PM ET
    $ALC
    Ophthalmic Goods
    Health Care